DA
CDAK

Denali Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Denali Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,100
Closed -$7K – 462
2022
Q3 		$7K Hold
9,100
– – ﹤0.01% 313
2022
Q2 		$26K Buy
9,100
+2,600
+40% +$9.13K 0.01% 282
2022
Q1 		$41K Buy
+6,500
New +$40.8K 0.02% 260

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Denali Advisors's CDAK Position: Q4 2022 in Review

Denali Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2022, closing a stake of 9,100 shares — an estimated $7K sold.

Denali Advisors first reported a position in CDAK in Q1 2022 and held it in 3 quarters. The position peaked at $41K in Q1 2022. 40 funds tracked by Wall St. Rank hold CDAK as of Q4 2022.

  • Denali Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Denali Advisors sold 9,100 Codiak BioSciences, Inc. Common Stock shares in Q4 2022, an estimated $7K.
  • Denali Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Denali Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $41K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2022.

Based on Denali Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.